American Heart Journal
Volume 157, Issue 1 , Pages 148.e1-148.e5 , January 2009

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

  • Jolanta M. Siller-Matula, MD

      Affiliations

    • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    • ,
  • Alexander O. Spiel, MD

      Affiliations

    • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    • ,
  • Irene M. Lang, MD

      Affiliations

    • Department of Cardiology, Medical University of Vienna, Vienna, Austria
    • ,
  • Gerhard Kreiner, MD

      Affiliations

    • Department of Cardiology, Medical University of Vienna, Vienna, Austria
    • ,
  • Guenter Christ, MD

      Affiliations

    • Department of Cardiology, Medical University of Vienna, Vienna, Austria
    • ,
  • Bernd Jilma, MD

      Affiliations

    • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationReprint requests: Bernd Jilma, MD, Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Received 24 August 2008 ,Accepted 25 September 2008.

References 

  1. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221–231
  2. Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost. 2007;97:385–393
  3. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J. 2008;156:S3–S9
  4. Gladding P, Webster M, Ormiston J, et al. Antiplatelet drug nonresponsiveness. Am Heart J. 2008;155:591–599
  5. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891–896
  6. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288–1295
  7. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475–484
  8. Lotfi A, Schweiger MJ, Giugliano GR, et al. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients—a Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008;155:954–958
  9. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827
  10. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–260
  11. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4:2508–2509
  12. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36
  13. Cairns JA, Eikelboom J. Clopidogrel resistance: more grist for the mill. J Am Coll Cardiol. 2008;51:1935–1937
  14. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–1834
  15. Manolopoulos P, Glenn JR, Fox SC, et al. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Platelets. 2008;19:134–145
  16. Sudo T, Ito H, Kimura Y. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets. 2003;14:381–390
  17. Judge HM, Buckland RJ, Sugidachi A, et al. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets. 2008;19:125–133
  18. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630–1636
  19. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404–1411
  20. Kleiman NS. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?. J Am Coll Cardiol. 2008;51:1412–1414
  21. Siller-Matula J, Lang I, Christ G, et al. Calcium channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557–1563
  22. Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardised reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets. 2008;19:551–554
  23. Morel O, Faure A, Ohlmann P, et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb. Haemost. 2007;98:896–899
  24. Seyfert UT, Haubelt H, Vogt A, et al. Variables influencing Multiplate (TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets. 2007;18:199–206
  25. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;99:121–126
  26. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–788
  27. Penz SM, Reininger AJ, Toth O, et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost. 2007;97:435–443
  28. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer-comparison with two flow cytometric methods. Thromb Res. 2007;121:249–258
  29. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28:966–972
  30. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32–37
  31. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007;50:291–295
  32. Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality?. J Am Coll Cardiol. 2007;50:296–298

 This study was supported by a grant from the Jubiläumsfond of the Austrian National Bank (Nr. 12565).

PII: S0002-8703(08)00822-3

doi: 10.1016/j.ahj.2008.09.017

American Heart Journal
Volume 157, Issue 1 , Pages 148.e1-148.e5 , January 2009

Article Tools

* Image Usage & Resolution